| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ruxolitinib | CTRPv2 | pan-cancer | AAC | -0.18 | 2e-06 |
| mRNA | CAL-101 | GDSC1000 | pan-cancer | AAC | 0.17 | 2e-06 |
| mRNA | ruxolitinib | GDSC1000 | pan-cancer | AAC | -0.17 | 5e-06 |
| mRNA | ZM-447439 | GDSC1000 | pan-cancer | AAC | -0.19 | 7e-06 |
| mRNA | ZSTK474 | CTRPv2 | pan-cancer | AAC | 0.17 | 2e-05 |
| mRNA | PD-0325901 | GDSC1000 | pan-cancer | AAC | -0.16 | 2e-05 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.16 | 2e-05 |
| mRNA | JNJ-26854165 | CTRPv2 | pan-cancer | AAC | 0.16 | 3e-05 |
| mRNA | Rapamycin | CTRPv2 | pan-cancer | AAC | 0.16 | 3e-05 |
| mRNA | A-770041 | GDSC1000 | pan-cancer | AAC | 0.24 | 3e-05 |